跳至主要内容
临床试验/NCT03481725
NCT03481725已完成不适用

Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacologic Alternative for the Treatment of Postoperative Pain

University of California, San Diego12 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2018年7月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
65
试验地点
12
主要终点
Opioid Consumption During First Postoperative Week

研究概览

简要总结

Postoperative pain is usually treated with opioids that have undesirable and sometimes dangerous side effects (e.g., vomiting and respiratory depression)-and yet over 80% of patients still experience inadequate pain relief. A novel, non-pharmacologic analgesic technique-percutaneous peripheral nerve stimulation (PNS)- holds extraordinary potential to greatly reduce or obviate opioid requirements and concurrently improve analgesia following painful surgery. This technique involves inserting an insulated electric lead adjacent to a target nerve through a needle prior to surgery using ultrasound guidance. Following surgery, a tiny electric current is delivered to the nerve resulting in potent pain control without any cognitive or adverse systemic side effects whatsoever. The electrical pulse generator (stimulator) is so small it is simply affixed to the patient's skin. The leads are already cleared by the US Food and Drug Administration to treat acute (postoperative) pain for up to 60 days; and, since percutaneous PNS may be provided on an outpatient basis, the technique holds the promise of providing potent analgesia outlasting the pain of surgery-in other words, the possibility of a painless, opioid-free recovery following surgery.

The current project is a multicenter, randomized, double-masked, placebo-controlled, parallel-arm clinical pilot study to (1) determine the feasibility and optimize the protocol of a planned definitive clinical trial; and (2) estimate the treatment effect of percutaneous PNS on pain and opioid consumption following moderate-to-severely painful ambulatory surgery compared with usual and customary opioid-based analgesia. This will allow determination of the required sample size for a subsequent definitive multicenter clinical trial. Combined, the pilot study and definitive trial have a strong potential to dramatically reduce or obviate postoperative opioid requirements and their resultant negative effects on both individuals and society; while concurrently improving analgesia, increasing the ability to function in daily life, decreasing the risk of transition from acute to chronic pain, and improving quality of life.

详细描述

This is a pilot or feasibility study (designated as UG3 by the Department of Defense) which will be a randomized, double-masked, placebo-controlled, parallel-arm, human subjects pilot study with two Specific Aims:

Specific Aim 1 (UG3): To determine the feasibility and optimize the protocol of the Implementation Phase (UH3) multicenter clinical trial that will compare percutaneous PNS with usual and customary opioid-based analgesia following moderate-to-severely painful ambulatory surgery.

Specific Aim 2 (UG3): To estimate the treatment effect of percutaneous PNS on pain and opioid consumption following moderate-to-severely painful ambulatory surgery compared with usual and customary opioid-based analgesia. This will allow determination of the required sample size of the definitive multicenter clinical trial of the Implementation Phase (UH3).

Anthropomorphic and demographic characteristics as well as baseline end points will be recorded/measured, including a pain score at the surgical site using the Numeric Rating Scale (NRS, 0-10), sensory deficits (measured with von Frey filaments within the cutaneous distribution of the target nerve), and muscle strength (measured with a pressure transducer).

Shoulder • Rotator cuff repair Brachial plexus trunks (lead & interscalene nerve block)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older
  • undergoing one of the following surgical procedures: rotator cuff repair, anterior cruciate ligament repair with a patellar autograph, ankle arthrodesis or arthroplasty, hallux valgus correction
  • with a planned single-injection peripheral nerve block for postoperative analgesia

排除标准

  • chronic analgesic use including opioids (daily use within the 2 weeks prior to surgery and duration of use > 4 weeks)
  • neuro-muscular deficit of the target nerve(s)
  • compromised immune system based on medical history (e.g., immunosuppressive therapies such as chemotherapy, radiation, sepsis, infection), or other conditions that places the subject at increased risk
  • implanted spinal cord stimulator, cardiac pacemaker/defibrillator, deep brain stimulator, or other implantable neurostimulator whose stimulus current pathway may overlap
  • history of bleeding disorder
  • antiplatelet or anticoagulation therapies other than aspirin due to the risk of bleeding with a 20-gauge insertion needle
  • allergy to skin-contact materials (occlusive dressings, bandages, tape etc.)
  • incarceration
  • chronic pain of greater than 3 months of any severity in an anatomic location other than the surgical extremity
  • anxiety disorder
  • history of substance abuse
  • inability to contact the investigators during the treatment period, and vice versa (e.g., lack of telephone access).

结局指标

主要结局

Opioid Consumption During First Postoperative Week

时间窗: Postoperative days 0-7

Cumulative opioid dose from days 0-7, collected on days 0, 1, 2, 3, 4, and 7 for the previous 24 hours at each time point measured in morphine equivalents

Average Pain During First Postoperative Week

时间窗: Postoperative days 0-7

Mean value of the "average" pain scores measured using the numeric rating scale, collected on days 0, 1, 2, 3, 4, and 7 for the previous 24 hours at each time point. This is a 0-10 Likert scale measuring pain level with 0 = no pain and 10 = worst imaginable pain

次要结局

  • Defense and Veterans Pain Rating Score(Postoperative days 3, and 7; as well as Months 1 and 4)
  • Opioid Consumption Individual Time Points(Postoperative days 1, 2, 3, 4, 7, 11, and 15; as well as Months 1 and 4)
  • Brief Pain Inventory, Short Form (Interference Domain)(Postoperative days 3, and 7; as well as Months 1 and 4)
  • Worst Pain at Individual Time Points(Postoperative days 1, 2, 3, 4, 7, 11, and 15; as well as Months 1 and 4)
  • Least Pain at Individual Time Points(Postoperative days 3 and 7; as well as Months 1 and 4)
  • Current Pain at Individual Time Points(Postoperative days 3 and 7; as well as Months 1 and 4)
  • Average Pain at Individual Time Points(Postoperative days 1, 2, 3, 4, 7, 11, and 15; as well as Months 1 and 4)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Brian M. Ilfeld, MD, MS

Professor of Anesthesiology, In Residence

University of California, San Diego

研究点 (12)

Loading locations...

相似试验